Table 3

Cardiovascular mortality risk when classified according to eGFR recalculated with cystatin C, as compared with creatinine

Evaluated (N)Reclassified to higher eGFR with cystatin CNot reclassifiedReclassified to lower eGFR with cystatin C
N (%)HR (95% CI)N (%)HR (95% CI)N (%)HR (95% CI)
862 events503 events
eGFRcrea ≥6012 710NANA10 560 (83)Ref2150 (17)3.14 (2.81 to 3.50)
eGFRcrea ≥60, adj12 710NANA10 560 (83)Ref2150 (17)1.59 (1.41 to 1.79)
80 events586 events291 events
eGFRcrea 30–592954440 (15)0.56 (0.45 to 0.71)1956 (66)Ref558 (19)2.06 (1.79 to 2.37)
eGFRcrea 30–59, adj2954440 (15)0.77 (0.61 to 0.98)1956 (66)Ref558 (19)1.77 (1.53 to 2.05)
40 events114 events104 events
eGFRcrea 20–29625165 (26)0.49 (0.34 to 0.71)269 (43)Ref191 (31)1.35 (1.04 to 1.77)
eGFRcrea 20–29, adj625165 (26)0.71 (0.49 to 1.02)269 (43)Ref191 (31)1.48 (1.13 to 1.94)
39 events235 events
eGFRcrea <20651154 (24)0.46 (0.33 to 0.64)497 (76)RefNANA
eGFRcrea <20, adj651154 (24)0.61 (0.43 to 0.87)497 (76)RefNANA
  • Adj=adjusted for age, gender, Charlson Comorbidity Index, and prior diagnosis of diabetes, obesity, hypertension or cardiovascular disease.

  • eGFR, estimated glomerular filtration rate; NA, not available.